Return to normal: COVID-19 vaccination under mitigation measures

Being unable to suppress SARS-CoV-2 transmission, the majority of countries worldwide have resorted to a mitigation approach towards COVID-19, allowing some degree of viral circulation in the population. Here, we investigate the expected outcomes of the interplay between vaccination rollout and adaptive mitigation measures constantly altering the epidemic trajectory and keeping the reproduction number around the unit. Using a novel mathematical modeling framework, we estimate that, for vaccination capacities of at least 4 daily doses administered per 1,000 inhabitants, a complete release of mitigation measures can be expected within 7 to 13 months since the start of vaccination, with a two-year cumulative incidence of deaths between 0.18 and 0.46 per 1,000 population. A heavier burden of deaths and a delayed <<return-to-normal>> is expected for lower vaccine capacities, if viral transmissibility exceeds by >60% the one estimated at the beginning of the pandemic, or if vaccine protection is short-lived. Failure to prioritize the elderly or a premature release of mitigation measures after vaccination of the most fragile will conspicuously increase the expected mortality. Finally, strategies oriented to prioritize the suppression of SARS-CoV-2 by maintaining strict restrictions will take a similar time as a mitigation approach, possibly resulting in acceptability issues. Persisting unknowns about the evolving epidemiology of SARS-CoV-2 variants and on the effectiveness of available and upcoming vaccines may warrant a future reassessment of these conclusions.

[1]  N. G. Davies,et al.  Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 , 2021, Nature.

[2]  C. Aschwanden Five reasons why COVID herd immunity is probably impossible , 2021, Nature.

[3]  Jonathan C. Brown,et al.  Effect of previous SARS-CoV-2 infection on humoral and T-cell responses to single-dose BNT162b2 vaccine , 2021, The Lancet.

[4]  A. Charlett,et al.  Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study) , 2021, SSRN Electronic Journal.

[5]  Y. Kreiss,et al.  Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients , 2021, The Lancet.

[6]  C. Viboud,et al.  Can a COVID-19 vaccination program guarantee the return to a pre-pandemic lifestyle? , 2021, Research square.

[7]  D. Ho,et al.  Antibody Resistance of SARS-CoV-2 Variants B.1.351 and B.1.1.7 , 2021, bioRxiv.

[8]  A. Charlett,et al.  Do antibody positive healthcare workers have lower SARS-CoV-2 infection rates than antibody negative healthcare workers? Large multi-centre prospective cohort study (the SIREN study), England: June to November 2020 , 2021, medRxiv.

[9]  J. Bloom,et al.  Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies , 2021, bioRxiv.

[10]  T. Blakely,et al.  Elimination could be the optimal response strategy for covid-19 and other emerging pandemic diseases , 2020, BMJ.

[11]  C. Macintyre,et al.  Modelling of COVID-19 vaccination strategies and herd immunity, in scenarios of limited and full vaccine supply in NSW, Australia , 2020, Vaccine.

[12]  D. Larremore,et al.  Model-informed COVID-19 vaccine prioritization strategies by age and serostatus , 2020, Science.

[13]  A. Vespignani,et al.  Infectivity, susceptibility, and risk factors associated with SARS-CoV-2 transmission under intensive contact tracing in Hunan, China , 2020, medRxiv.

[14]  S. Bhatt,et al.  Estimating the effects of non-pharmaceutical interventions on COVID-19 in Europe , 2020, Nature.

[15]  B. Pfefferbaum,et al.  Mental Health and the Covid-19 Pandemic. , 2020, The New England journal of medicine.

[16]  V. Colizza,et al.  A race between SARS-CoV-2 variants and vaccination: The case of the B.1.1.7 variant in France , 2021 .